Age (years)
|
67 ± 7.8
|
66 ± 9.7
|
0.917
|
Male gender, n (%)
|
7 (70%)
|
14 (45%)
|
0.172
|
Body mass index (kg/m2)
|
28 ± 5.1
|
28 ± 4.0
|
0.580
|
BSA (m2)
|
2 ± 0.3
|
2 ± 0.2
|
0.580
|
Prothesis size [mm]
|
24 ± 2
|
23 ± 2
|
0.247
|
Biological prosthesis, n (%)
|
10 (100%)
|
29 (94%)
|
0.410
|
Prosthesis type Medtronic biological, n (%)
|
1 (10%)
|
0 (0%)
|
0.075
|
Prosthesis type Medtronic mechanical, n (%)
|
0 (0%)
|
1 (3%)
|
0.565
|
Prosthesis type Edwards, n (%)
|
2 (20%)
|
7 (23%)
|
0.864
|
Prosthesis type SJM regent, n (%)
|
0 (0%)
|
1 (3%)
|
0.565
|
Prosthesis type Trifecta, n (%)
|
5 (50%)
|
16 (52%)
|
0.929
|
Prosthesis type CE Perimount Magna Ease, n (%)
|
2 (20%)
|
6 (19%)
|
0.964
|
Risk factors
|
Bicuspid aortic valve, n (%)
|
8 (80%)
|
23 (74%)
|
0.710
|
Dyslipidaemia, n (%)
|
7 (70%)
|
13 (42%)
|
0.123
|
Diabetes mellitus, n (%)
|
2 (20%)
|
2 (6%)
|
0.209
|
Arterial hypertension, n (%)
|
8 (80%)
|
21 (68%)
|
0.459
|
CCS III-VI, n (%)
|
1 (10%)
|
2 (6%)
|
0.708
|
NYHA III-IV, n [%]
|
5 (50%)
|
13 (42%)
|
0.655
|
Medical Treatment
|
Betablocker, n (%)
|
4 (40%)
|
13 (42%)
|
0.914
|
Calcium antagonist, n (%)
|
1 (10%)
|
3 (10%)
|
0.976
|
Diuretics, n (%)
|
3 (30%)
|
8 (26%)
|
0.795
|
ARB, n (%)
|
3 (30%)
|
6 (19%)
|
0.479
|
ACE-I, n (%)
|
4 (40%)
|
7 (23%)
|
0.280
|